Why March 31 Is a Critical Date for Medicare Advantage Plan Enrollees

Medicare Advantage’s Open Enrollment runs Jan. 1–Mar. 31, during which current enrollees may make one change — either switch to a different Advantage plan or move to original Medicare (with or without Part D). Beneficiaries generally cannot change standalone Part D coverage during this period; roughly 90% of Advantage plans in 2025 included prescription drug benefits, and missing the March 31 deadline typically forces a wait until the October enrollment window or a qualifying special enrollment period, posing material timing risk to retirees’ out-of-pocket healthcare costs.

Analysis

Market structure: The Jan 1–Mar 31 Medicare Advantage (MA) window advantages incumbent MA-focused insurers (UNH, HUM, CVS) and PBMs that bundle Part D; smaller regional carriers and stand-alone Medigap providers face potential share loss. A 0.5–2.0 percentage-point shift in MA share across a major issuer can move MA revenue by low-single-digit % for the year (material for names trading at 15–20x EPS). Demand remains structurally strong from aging cohorts; supply is constrained by provider network capacity and CMS star-rating incentives that concentrate flows to higher-rated plans.

Risk assessment: Key tail risks are swift CMS regulatory changes (payment rate cuts or rating methodology shifts), network disruption (provider exits), or litigation that could reverse enrollee flows — each could compress EBITDA by >10% at exposed names. Time horizons: immediate (days–weeks) for consumer switching around Mar 31; short-term (Apr–Jun) when monthly/quarterly enrollment disclosures arrive; long-term (2025–2027) for secular MA penetration. Hidden dependency: star ratings and Part D inclusion (~90% prevalence) materially mute switching; monitor star releases and CMS memos as high-leverage catalysts.

Trade implications: Favor overweight MA-centric insurers: initiate 2–3% long positions in HUM and 1–2% in UNH sized to portfolio volatility, target 20–30% upside over 6–12 months, stop-loss 12%. Pair trade: long HUM (1.5%) vs short ELV (1.5%) if April membership shows HUM +0.5ppt share gain; unwind if reversal >1ppt. Options: buy Jun 2026 6–10% OTM call spreads on HUM/UNH (0.5–1% notional) to capture upside while capping premium; sell into post-April enrollment prints.

Contrarian angles: The market often overreacts to enrollment noise; since ~90% of MA plans include Part D, actual churn is limited so share moves are incremental not structural — downward re-rates could be overdone. Historical parallels: past Q1 MA windows produced small stock moves until confirmed by monthly membership releases; disproportionate moves that are >10% without enrollment confirmation are trading opportunities to fade. Unintended consequence: aggressive enrollee switching could temporarily raise utilization and near-term medical loss ratios, pressuring margins for the next 1–2 quarters.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in HUM (Humana) and a 1–2% long in UNH (UnitedHealth) before April 15; set tactical profit target 20–30% within 6–12 months and a stop-loss at 12% to reflect modest upside from MA enrollment momentum and star-rating tailwinds.
• Initiate a relative-value pair: long HUM (1.5%) vs short ELV (Elevance) (1.5%) conditional on April membership prints showing HUM +0.5ppt sequential MA share gain; cover if the spread widens beyond 1ppt or after the next quarterly earnings release.
• Purchase Jun 2026 6–10% OTM call spreads on HUM and UNH sized to 0.5–1% of portfolio each to capture upside from confirmed enrollment gains; sell into strength after April/May monthly enrollment reports or if implied volatility spikes >25%.
• Reduce exposure by 2–4% to regional hospital operators and stand-alone Medigap/ancillary insurers that have >30% revenue from fee-for-service seniors, reallocating proceeds to MA-focused insurers; reassess after CMS star-rating and payment announcements (monitor next 30–60 days).